Shield Therapeutics has announced that the US FDA has approved the extension of the indication for ACCRUFeR® to include adolescents following a priority review of the clinical supplement. We view this as a significant advance for Shield as the wider story of commercial traction and development continues, supported by the strength of the scientific evidence base. We maintain our investment thesis and look to further updates from the company in due course.